Thermo Fisher Scientific Inc. $TMO Shares Sold by Freedom Investment Management Inc.

Freedom Investment Management Inc. lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.1% in the 1st quarter, HoldingsChannel reports. The fund owned 3,356 shares of the medical research company’s stock after selling 335 shares during the period. Freedom Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $1,670,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $35,000. Finally, Navigoe LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 295 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total transaction of $147,511.80. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,591,606.96. The trade was a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,896 shares of company stock worth $8,593,838. 0.33% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a report on Friday, July 11th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Robert W. Baird upped their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Finally, HSBC restated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $593.00.

Thermo Fisher Scientific Stock Up 3.4%

Shares of Thermo Fisher Scientific stock opened at $500.2380 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a market cap of $188.89 billion, a P/E ratio of 28.93, a PEG ratio of 2.67 and a beta of 0.74. The firm has a fifty day moving average of $443.02 and a two-hundred day moving average of $455.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm’s revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.